Investors intrigued by the buzz surrounding a new breed of startups developing medications based on psychedelics can expect new opportunities to invest in the sector this year. Mind Medicine Inc. (MindMed), whose backers include entrepreneur Kevin O’Leary of “Shark Tank” fame, has become the first psychedelics pharmaceutical firm to go public. The Toronto-based company, which is developing “psychedelic-inspired medicines” to combat opioid addiction and other disorders, completed its initial public offering March 3 on the NEO Exchange in Canada. (NEO is the favored stock exchange for the cannabis industry, which cannot float shares in the United States because of lingering legal issues. NEO expects to add more medical psychedelic firms to its market in coming months.)